GlobeNewswire

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
06/11/2026
– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Orphan Medicinal Products ( [...]
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
06/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
MIMEDX to Participate in Upcoming Investor Conferences
06/11/2026
MARIETTA, Ga., Nov. 06, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Regenerative Ophthalmology Takes Center Stage This November 7 at the Next Generation Medicine Congress 2026 in Dubai
06/11/2026
DUBAI, United Arab Emirates, Nov. 06, 2026 (GLOBE NEWSWIRE) -- As the globe moves to the era of cellular restoration in healthcare, Next Generation Medicine Congress 2026 decided to dedicate November 7–10, 2026, to four [...]
Notice of Annual General Meeting 2026
06/11/2026
The Annual General Meeting of Coloplast A/S will be held on Tuesday, 1 December 2026 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/11/2026
SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2 [...]
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
06/11/2026
Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling Pharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluated Findings [...]
Davion Healthcare Plc Appoints Vienna Capital Partners to Support US$100 Million Acquisition Financing Strategy
06/11/2026
Financial advisory appointment to support planned acquisitions of profitable, revenue-generating businesses during 2027 DUBLIN, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “ [...]
Groundbreaking therapy for advanced heart failure: Repairon’s Scientific Co-Founder, Prof. Wolfram-Hubertus Zimmermann, Receives the 2026 “Galenus-von-Pergamon” Award for Outstanding Basic Pharmacological Research
06/11/2026
GÖTTINGEN, Germany and PROVIDENCE, R.I., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Professor Zimmermann and his research team are recognized for the development of iPSC-derived engineered heart muscle, Repairon’s BioVAT lead [...]
Major shareholder announcement - BlackRock, Inc.
06/11/2026
ANNOUNCEMENT NO. 326 6 November 2026 Pursuant to section 30 of the Danish Capital Markets Act, notice is hereby given that BlackRock, Inc. has notified ChemoMetec A/S that, on 2 November 2026, BlackRock, Inc. reduced [...]
Nature Medicine Publication Reveals How Human Movement Predicts Hidden Biosignals Spanning 18 Body Systems, from Heart and Liver Function to Metabolic and Mental Health
06/11/2026
Peer-reviewed study of 3,328 adults links subtle movement patterns to 1,887 health measures and finds independent predictive information across nearly every major body system evaluated Newton Tech is translating this [...]
Nxera Pharma Announces Vamorolone Selected for South Korea’s Accelerated Reimbursement Pilot Program for Rare Disease Treatments
06/11/2026
Vamorolone is one of five treatments selected for the rare disease reimbursement pilot program. The program aims to shorten the National Health Insurance listing process to within 100 days. Together with GIFT priority [...]
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
06/11/2026
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, [...]
Le KFSH de Riyad figure parmi les 5 % des meilleurs établissements de santé au monde pour le tourisme médical selon le classement 2027 de Newsweek
06/11/2026
RIYAD, Arabie saoudite, 06 nov. 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) de Riyad se classe parmi les 5 % des meilleurs établissements de santé répertoriés dans l’édition [...]
Avance Clinical Brings 30 Years of Early-Phase and Therapeutic Leadership to European Biotechs at BIO-Europe 2026
06/11/2026
Australian fast-start pathway, four Centers of Excellence and a GlobalReady model that takes programs from first-in-human to global Phase II without changing CROs ADELAIDE, Australia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- [...]
MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.
06/11/2026
Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kg Joenja is expected to become available to patients covered by the expanded indication in February 2027 [...]
Orchestra BioMed Announces Pricing of Public Offering
06/11/2026
NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum